Companies ›Healthcare ›TLPH.O

TLPH.O — NASDAQ Diversified Pharmaceuticals

Talphera Inc

$1,31

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

68,0M USD

P/E

—

EV / Rev

1 230,6x

Div yield

—

Op margin

—

ROE

-24,2 %

Net margin

—

Debt / equity

0,00

Beta

—

52w range

—

Volume

1,6k

Day range

$0,80–$0,84

Prev close

$0,82

Open

$0,83

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

Talphera Inc is a pharmaceutical company focused on the development and commercialization of innovative therapies for unmet medical needs.

Business. Talphera Inc (TLPH.O) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification99 %

SectorHealth Care

Industry groupDiversified Pharmaceuticals

Generated · model-assisted

Sell-side consensus

BUY2 analysts

2 buy0 hold0 sell

Avg 12m price target3,25

Analyst recommendations

2 analysts · consensus Buy

Buy2

Hold0

Sell0

12-month price target

3,25

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

2 analysts · indicative

Ownership→

Geode Capital Management, L.L.C.

largest disclosed fund holder

Profitability→

-24,2 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning TLPH.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to TLPH.O. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Talphera Inc (TLPH.O) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification99 %

SectorHealth Care

Industry groupDiversified Pharmaceuticals

AI synthesis

GENERATED

Talphera operates with a strong liquidity position, as evidenced by its cash and equivalents of $12.12 million, which represents 42.1% of its total assets. The company has no long-term debt, and its debt-to-equity ratio is 0.0, indicating a conservative capital structure. The current ratio of 5.97 suggests that the company has more than sufficient current assets to cover its current liabilities.

Despite its strong liquidity, Talphera is currently unprofitable, with a net loss of $3.95 million and an operating loss of $2.99 million in the latest reporting period. The company's return on equity (ROE) is -24.21%, and its return on assets (ROA) is -13.74%, both significantly below the industry median for pharmaceutical firms. The EV/EBITDA ratio is negative at -11.52, reflecting the company's current unprofitability and lack of positive cash flow.

Talphera's revenue is not disclosed in the latest financials, and no segment or geographic breakdown is available in the provided data. However, the absence of segment-specific data suggests that the company may be in an early stage of development or may not have disclosed such information in its latest filings.

The company's growth trajectory is uncertain, as no revenue history is provided. Analysts have assigned a mean price target of $3.25, with a median of $3.25, suggesting a potential upside from the current market price of $0.8975. However, the lack of positive earnings and operating cash flow raises concerns about the company's ability to sustain growth in the near term.

Talphera's risk profile is currently low in terms of liquidity and dilution, with no immediate filing-based flags detected. The company has not issued any new shares in the latest period, and its diluted share count is equal to its basic share count, indicating no dilution pressure at this time. However, the company's negative net income and operating cash flow could become a concern if it requires additional capital in the future.

No recent events, such as earnings calls, regulatory filings, or major business developments, are disclosed in the provided data. The company's financials suggest it is in a development or early commercialization phase, with no significant capital expenditures reported in the latest period.

Key takeaways

Talphera has a strong liquidity position with $12.12 million in cash and no long-term debt.
The company is currently unprofitable, with a net loss of $3.95 million and a negative ROE of -24.21%.
Analysts have assigned a mean price target of $3.25, suggesting potential upside from the current market price of $0.8975.
The company has no immediate liquidity or dilution risks, but its negative cash flow could become a concern if it requires additional capital.

Bull / Bear case

Generated · model-assisted

BULL CASE · 5

Analysts project 149.6% upside to a mean price target of $3.25, signaling strong institutional confidence in future valuation recovery.

The company maintains zero long-term debt, resulting in a debt-to-equity ratio of 0.0, which significantly reduces financial leverage risk.

A current ratio of 5.49 indicates robust short-term liquidity, providing ample buffer to meet immediate operational obligations without distress.

Operating income improved by 3.7% year-over-year in the latest period, suggesting a marginal stabilization in core operational cost management.

Dilution and liquidity risks are assessed as low, indicating manageable shareholder equity structure and sufficient market trading depth.

BEAR CASE · 1

The company faces high credit risk, reflecting significant concerns regarding its ability to meet long-term financial obligations and solvency.

In focus — financials by report

Quarterly

Annual

QUARTERLYFiled 2026-03-23

Q4 2025 · Quarter highlights

Open report →

Revenue $0.00; Operating income −15,2% YoY.

Revenue$0.00

Operating income-$3.5M−15,2 % YoY

Net income-$3.8M−101,7 % YoY

Free cash flow-$3.8M−101,7 % YoY

EPS—

Operating cash flow-$11.4M+10,4 % YoY

Financials

Income statement

Revenue$0.00

Gross profit—

Operating income-$3.5M

Net income-$3.8M

Balance sheet

Total assets$29.7M

Total liabilities$12.7M

Total equity$17.0M

Cash & equivalents$5.9M

Long-term debt$0.00

Cash flow

Operating cash flow-$11.4M

CapEx—

Free cash flow-$3.8M

SBC—

Highlights

▍Revenue $0.00
▍Operating income −15,2% YoY
▍Net income −101,7% YoY
▍Free cash flow −101,7% YoY

Valuation TTM

Market price

$1,31

Market cap

$46.6M

Enterprise valueⓘ

$34.5M

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

1230.6x

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

2.9x

P / Tangible bookⓘ

2.9x

Tangible book

$16.3M

Net cashⓘ

$12.1M

Current ratioⓘ

6.0

Debt / equityⓘ

0.0

ROAⓘ

-13.7%

ROEⓘ

-24.2%

Cash conversionⓘ

73.0%

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%